Central Nervous System (CNS) comprises brain and spinal cord and it plays a vital role by acting as a control centre in the body. Any damage to CNS can cause malfunction in motor functions resulting in poor coordination between different parts of the body. Infections, degeneration, tumours, structural defects or auto-immune disorders can directly affect CNS resulting in neurological or psychiatric disorders. These disorders can be classified as vascular, infections, structural, functional and degenerative. Common CNS disorders are Alzheimer, Parkinson’s disease, diabetic neuropathy, multiple sclerosis, major depressive disorder (MDD), schizophrenia, insomnia, attention deficit hyperactivity disorder (ADHD), migraine, epilepsy, dementia, bipolar disorder, Huntington's disease, peripheral neuropathy, spinal stenosis, postherpetic neuralgia, cerebrovascular disease, depression, etc. Out of these, Parkinson’s and Alzheimer’s are the top CNS disorders globally.
CNS disorder drugs market is categorized into three segments namely psychiatry, neurology and pain drugs. Psychiatry captures around 40% of the CNS disorder drug market followed by neurology and pain drugs. Increasing aging population, developments in drug delivery methods, growing healthcare expenditure and rising incidence of CNS disorders are the major drivers of CNS disorder drugs market.
CNS drugs are either administered directly or systematically through intravenous injection. Drug delivery to CNS faces some challenges because of blood-brain barrier (BBB), which limits proper administering of drugs to the CNS. Many studies are going on to understand the cell biology of BBB, which are expected to open up possibilities for better drug delivery. Cell, gene and antisense therapies with sophisticated drug delivery methods are emerging as the potent treatment for CNS disorders.
At diagnostics level, biomarkers are emerging as a major indicator for early diagnosis and ascertaining the developmental stages of CNS disorders. Advances in genomics, proteomics and advanced imaging techniques like MRI, using biomarkers have enabled development of new anti-depressants, antipsychotics and anti-anxiety drugs. High cost may hinder overall growth of CNS biomarker market.
ASDReport.com has an extensive array of reports on Central Nervous System. The reports provides insights on various therapies and topics related to CNS like, neurone disease, seizures, neuropathy, sedation, cerebral palsy, spinal stenosis, among others.